This study is an open-label, single ascending dose (SAD) study designed to evaluate the safety and tolerability of ART002g1 in patients with heterozygous familial hypercholesterolemia (HeFH) who require further reduction in low-density lipoprotein cholesterol (LDL-C). ART002g1 uses base editing technology, which is designed to interfere with the expression of the PCSK9 gene in the liver, thereby reducing the circulating levels of PCSK9 and LDL-C. The primary objectives of this study are to determine the safety and pharmacodynamic (PD) profiles of ART002g1 in this patient population.
Male or female, aged 18 to 70 years (inclusive) at the time of signing the Informed Consent Form (ICF);
Body weight between 45 and 90 kg (inclusive) at screening;
Serum LDL-C ≥ 4.7 mmol/L without prior lipid-lowering treatment;
Cutaneous or tendinous xanthomas, or arcus cornealis (in subjects < 45 years old);
Diagnosis of compound heterozygous FH, double heterozygous FH, or homozygous FH (HoFH);
Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer ≥ 1 × 10² copies/L; positive for hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody;
Any unstable systemic disease, including but not limited to: unstable angina; cerebrovascular accident or transient ischemic attack (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening); history of heart failure (NYHA Class II-IV); severe arrhythmia requiring pharmacotherapy; liver, kidney, or metabolic diseases; or other unstable systemic diseases as determined by the investigator;
History of percutaneous transluminal coronary angioplasty (PTCA), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) within 6 months prior to the first dose; or documented severe coronary artery stenosis as confirmed by coronary CT or coronary angiography within 90 days prior to randomization.
Sequential
ART002g1 Injection
DrugIntravenous (IV) infusion
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: Tmax
Pharmacodynamic (PD) Assessments: Serum PCSK9 protein
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: Cmax
Pharmacokinetic (PK) Assessments: PK Parameters of ART002g1: AUC
Click on the lead sponsor to view all of their trials.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead sponsor
Accuredit Therapeutics US Limited
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
